A novel design of targeted endocrine and cytokine therapy for breast cancer

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1196-1205

  Zhang, Guorong ^a   Li, Wei ^a   Holle, Lori ^a   Chen, Nianyi ^a   Chen, Wen Yuan ^a  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G129R INTERLEUKIN 12 FUSION PROTEIN; HYBRID PROTEIN; PROLACTIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; GENE SEQUENCE; GROWTH RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FEMALE; HUMANS; INTERLEUKIN-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MILK PROTEINS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROLACTIN; RECOMBINANT FUSION PROTEINS; STAT5 TRANSCRIPTION FACTOR; TIME FACTORS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0036554708     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Forrest. P. Introduction to breast cancer. In: S. P. Langdon, W. R. Miller, and A. Berchuck (eds.), Biology of Female Cancers, pp. 31-42. Boca Raton, FL: CRC Press LLC, 1997.
2. Miller, W. R., and Langdon. S. P. In: S. P. Langdon, W. R. Miller, and A. Berchuck (eds.), Biology of Female Cancers, pp. 43-60. Boca Raton, FL: CRC Press LLC, 1997.
3. Clevenger, C. V., Chang, W. P., Ngo, W., Pasha, T. L., Montone, K. T., and Tomaszewski, J. E. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am. J. Pathol, 146: 695-705, 1995.
4. Ginsburg, E., and Vonderhaar, B. K. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res., 55: 2591-2595, 1995.
5. Vonderhaar, B. K. Prolactin: the forgotten hormone of human breast cancer. Pharmacol. Ther., 79: 169-178, 1998.
6. Vonderhaar, B. K. Prolactin involvement in the breast. Endocr.-Related Cancer. 6: 389-404, 1999.
7. Llovera, M., Touraine, P., Kelly, P. A., and Goffin, V. Involvement of prolactin in breast cancer: redefining the molecular targets. Exp. Gerontol., 35: 41-51, 2000.
8. Ormandy, C. J., Hall, R. E., Manning, D. L., Robertson, J. F. R., Blamey, R. W., Kelly, P. A., Nicholson, R. I., and Sutherland, R. L. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J. Clin. Endocrinol. Metab., 82: 3692-3699, 1997.
9. Wennbo, H., Gebre-Medhin, M., Gritli-Linde, A., Ohlsson, C., Isaksson, O. G., and Tornell, J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Investig., 100: 2744-2751, 1997.
10. Chen, W. Y., Ramamoorthy, P., Chen, N., Sticca, R., and Wagner, T. E. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res., 5: 3583-3593, 1999.
11. Horseman, N. D. Prolactin, proliferation, and protooncogenes. Endocrinology, 136: 5249-5251, 1995.
12. Horseman, N. D., Zhao, W., Montecino-Rodriguez, E., Tanaka, M., Nakashima, K., Engle, S. J., and Smith, F. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J., 16: 6926-6935, 1997.
13. Kelly, P. A., Djiane, J., Postel-Vinay, M. C., and Edery, M. The prolactin/growth hormone receptor family. Endocr. Rev., 12: 235-251, 1991.
14. Ali, S., Edery, M., Pellegrini, I., Lesueur, L., Paly, J., Djiane, J., and Kelly, P. A. The Nb2 form of prolactin receptor is able to activate a milk protein gene promoter. Mol. Endocrinol., 6: 1242-1248, 1992.
15. Bole-Feysot, C., Goffin, V., Edery, M., Binart, N., and Kelly, P. A. Prolactin (PRL), and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev., 19: 225-268, 1998.
16. Ormandy, C. J., Camus, A., Barra, J., Damotte, D., Lucas, B., Buteau, H., Edery, M., Brousse, N., Babinet, C., Binart, N., and Kelly, P. A. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev., 15: 167-178, 1997.
17. Chen, W. Y., Wight, D. C., Wagner, T. E., and Kopchick, J. J. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc. Natl. Acad. Sci. USA, 87: 5061-5065, 1990.
18. Chen, W. Y., Wight, D. C., Chen, N. Y., Wagner, T. E., and Kopchick, J. J. Mutations in the third α-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic mice. J. Biol. Chem., 266: 2252-2258, 1991.
19. Chen, W. Y., White, M. E., Wagner, T. E., and Kopchick, J. J. Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in transgenic dwarf mice. Endocrinology, 129: 1402-1408, 1991.
20. Chen, W. Y., Wight, D. C., Mehta, B. V., Wagner, T. E., and Kopchick, J. J. Glycine 119 of bovine growth hormone is critical for growth promoting activity. Mol. Endocrinol., 5: 1845-1852, 1991.
21. Chen, W. Y., Chen, N. Y., Yun, J., Wagner, T. E., and Kopchick, J. J. In vitro and in vivo studies of antagonists effects of human growth hormone analogs. J. Biol. Chem., 269: 15892-15897, 1994.
22. Chen, W. Y., Chen, N. Y., Yun, J., Wight, D. C., Wang, X. Z., Wagner, T. E., and Kopchick, J. J. Amino acid residues in the third α-helix of growth hormone involved in growth promoting activity. Mol. Endocrinol., 9: 292-302, 1995.
23. Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., Besser, G. M., Scarlett, J. A., Thorner, M. O., Parkinson, C., Klibanski, A., Powell, J. S., Barkan, A. L., Sheppard, M. C., Malsonado, M., Rose, D. R., Clemmons, D. R., Johannsson, G., Bengtsson, B. A., Stavrou, S., Kleinberg, D. L., Cook, D. M., Phillips, L. S., Bidlingmaier, M., Strasburger, C. J., Hackett, S., Zib, K., Bennett, W. F., and Davis, R. J. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med., 342: 1210-1211, 2000.
24. Goffin, V., Kinet, S., Ferrag, F., Binart, N., Martial, J. A., and Kelly, P. A. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J. Biol. Chem., 27: 16573-16579, 1996.
25. Chen, N. Y., Holle, L., Li, W., Peirce, S., Beck, M., and Chen, W. Y. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int. J. Oncol., in press, 2002.
26. Cataldo, L., Chen, N. Y., Li, W., Wagner, T. E., Sticca, R. P., and Chen, W. Y. Inhibition of the oncogene STAT3 by a human prolactin (PRL) antagonist is a PRL receptor specific event. Int. J. Oncology, 17: 1179-1185, 2000.
27. Ramamoorthy, P., Sticca, R. P., Wagner, T. E., and Chen, W. Y. In vitro studies of a prolactin antagonist, hPRL-G129R, in human breast cancer cells. Int. J. Oncol., 18: 25-32, 2001.
28. Llovera, M., Pichard, C., Bernichtein, S., Jeay, S., Touraine, P., Kelly, P. A., and Goffin, V. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene, 19: 4695-4705, 2000.
29. Davis, I. D. An overview of cancer immunotherapy. Immunol. Cell Biol., 78: 179-195, 2000.
30. Jaffee, E. M. Immunotherapy of cancer. Ann. N. Y. Acad. Sci., 886: 67-72, 1999.
31. Taniguchi, T., Matsui, H., Fujita, T., Fakaoka, C., Kashima, N., Yoshimoto, R., and Hamuro, J. Structure and expression of a cloned cDNA for human interleukin-2. Nature (Lond.), 302: 305-310, 1983.
32. Hendrzak, J. A., and Brunda, M. J. Interferons and other cytokines. In: B. Teicher (ed.), Cancer Therapeutics: Experimental and Clinical Agents, pp. 263-282. Totowa, NJ: Humana Press Inc., 1997.
33. Maas, R. A., Becker, M. J., Weimar, I. S., De Nooy, J. C., Dullens, H. F., and Den Otter, W. D. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL2 therapy of tumor bearing mice. Immunobiology, 188: 281-292, 1993.
34. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., and Seipp, C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med., 319: 1676-1680, 1988.
35. Zhou, Y., Xu, B., Wang, X., Chen, W. Y., and Kopchick, J. J. Functional expression of a mouse growth hormone receptor cDNA in transfected mouse L cells. Receptor, 4: 143-155, 1994.
36. Overwilk, W. W., Theoret, M. R., and Restifo, N. P. The future of intrleukin-2: enhancing therapeutic anticancer vaccines, Cancer J. Sci. Am., 6 (Suppl. 1): S76-S80, 2000.
37. Bremers, A. J., and Parmiani, G. Immunology and immunotherapy of human cancer: present concepts and clinical development. Crit. Rev. Oncol. Hematol., 34: 1-25, 2000.
38. Kawakami, Y. New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system. Cornea, 19 (Suppl.): S2-S6, 2000.
39. Boon, T. Toward a genetic analysis of human tumor rejection antigens. Adv. Cancer Res., 58: 177-210, 1992.
40. Urban, J. L., and Schreiber, H. Tumor antigens. Annu. Rev. Immunol., 10: 617-644, 1992.
41. Mosmann, T. R., and Coffman, R. L. Th1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 7: 145-173, 1989.
42. Reisfeld, R. A., and Gillies, S. D. Recombinant antibody fusion proteins for cancer immunotherapy. Curr. Top. Microbiol. Immunol., 213: 27-53, 1996.
43. Reisfeld, R. A., Becker, J. C., and Gillies, S. D. Immunocytokines: a new approach to immunotherapy of melanoma. Melanoma Res., 2 (Suppl.): S99-S106, 1997.
44. Dolman, C. S., Mueller, B. M., Lode, H. N., Xiang, R., Gillies, S. D., and Reisfeld, R. A. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin. Cancer Res., 4: 2551-2557, 1998.
45. Xiang, R., Lode, H. N., Dreier, T., Gillies, S. D., and Reisfeld, R. A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res., 58: 3918-3925, 1998.
46. Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D., and Reisfeld, R. A. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther., 80: 277-292, 1998.
47. Lode, H. N., and Reisfeld, R. A. Targeted cytokines for cancer immunotherapy. Immunol. Res, 21: 279-288, 2000.
48. Xu, X. C., Clarke, P., Szalai, G., Shively, J. E., Williams, Shyr, Y., Shi, E., and Primus, F. J. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res., 60: 4475-4484, 2000.
49. Gillies, S. D., Reilly, E. B., Lo, K. M., and Reisfeld, R. A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA, 89: 1428-1432, 1992.
50. Lode, H. N., Xiang, R., Duncan, S. R., Theofilopoulos, A. N., Gillies, S. D., Reisfeld, R. A. Tumor-targeted IL2 amplifies, T. cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA, 96: 8591-8596, 1999.
51. Kobayashi, H., Carrasquillo, J. A., Paik, C. H., Waldmann, T. A., and Tagaya, Y. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res., 60: 3577-3583, 2000.